Jennifer Lee
Jennifer Lee is a rockstar in pharma and has successfully taken new products from bench to patients numerous times. Her extensive global drug development experience, executive leadership, and international regulatory perspective qualify her to serve on a public board, including risk committee, nominating and governance and audit committee
Jennifer Lee has over 25 years of life sciences experience developing clinical strategies into new products, initiating new drug applications, and translating life sciences research discoveries into business opportunities. Accelerated numerous therapeutics resulted in progression to regulatory filings and approvals of 7 novel treatments (Celebrex®, Myrbetriq®, Betmiga®, Xtandi®, among others) that contributed over $20 billion in revenue. With senior-level experience at Top 50 Global Pharma Companies (Pfizer, Gilead, Astellas) and midsize and startup companies, Jennifer Lee has successfully advanced numerous product candidates and successfully driving labeling changes, licensing agreements, and market registrations. She has contributed to numerous international regulatory inspections for FDA, EMA, MHRA, China, Japan, South Korea, and other countries.
Jennifer has her board certification from Corporate Directors International LLC, USA. Her designation, CDI.D, recognizes her as a qualified corporate board candidate for a public or private board.